Inflammasome

Aus coViki
Version vom 11. April 2021, 20:22 Uhr von Ossip Groth (Diskussion | Beiträge)
(Unterschied) ← Nächstältere Version | Aktuelle Version (Unterschied) | Nächstjüngere Version → (Unterschied)
Wechseln zu: Navigation, Suche
PHA Biologicals
Colchicine
32493814 2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.


32574259 2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
32655582 2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.
32670297 2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
32744716 2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
32776354 2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
32824985 2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
32841451 2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.
32965010 2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
32980515 2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
33066442 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.
33099890 2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis